EVALUATION OF ADENOVIRAL VECTOR-BASED VACCINES FOR PREVENTION OF COVID-19 – AN OVERVIEW

The novel coronavirus and its emerging variants have continued to affect 50.4 million people worldwide, increasing the need for safe and effective vaccines. According to the World Health Organization guidelines, the efficacy of a vaccine should be at least 30% in all age groups and protect for a lon...

Full description

Saved in:
Bibliographic Details
Published inAsian journal of pharmaceutical and clinical research pp. 6 - 16
Main Authors SHANMUGAM, SINDHU, VENUGOPAL, PRIYANKA, SRIRAM, DAMAL KANDADAI, GEORGE, MELVIN
Format Journal Article
LanguageEnglish
Published 07.07.2022
Online AccessGet full text

Cover

Abstract The novel coronavirus and its emerging variants have continued to affect 50.4 million people worldwide, increasing the need for safe and effective vaccines. According to the World Health Organization guidelines, the efficacy of a vaccine should be at least 30% in all age groups and protect for a longer duration without any life-threatening adverse effects. At present, there are 319 vaccines in various stages of development, of which 16 are authorized for emergency use. Of these 16 vaccines, five vaccines are based on adenoviral vectors. This review is focused on understanding the safety and efficacy of the approved adenoviral vector vaccines for COVID-19, particularly highlighting the interim analysis of phase 3 clinical trials of AZD1222, Gam-Covid-Vac, Ad26.COV2.S, and AD5-nCOV vaccine. The efficacy of AZD1222, Gam-Covid-Vac, Ad26.COV2.S, and AD5-nCOV vaccine were found to be 70.4%, 95%, 66%, and 65.7%, respectively. Some serious adverse events such as deep vein thrombosis and thrombosis with thrombocytopenia syndrome were observed among AZD1222 and Ad26.COV2.S vaccinated individuals. Meanwhile, Gam-Covid-Vac and AD5- nCOV vaccines did not report any significant adverse events. In addition, we have also focused on the efficacy of these vaccines against SARS-CoV-2 variants such as B.1.1.7, B.1.351, and P.1. Although the efficacy of these approved vaccines against novel SARS-CoV-2 variants, pediatric and geriatric population and long-term efficacy remains uncertain, they are reasonably efficient in preventing mortality due to COVID-19.
AbstractList The novel coronavirus and its emerging variants have continued to affect 50.4 million people worldwide, increasing the need for safe and effective vaccines. According to the World Health Organization guidelines, the efficacy of a vaccine should be at least 30% in all age groups and protect for a longer duration without any life-threatening adverse effects. At present, there are 319 vaccines in various stages of development, of which 16 are authorized for emergency use. Of these 16 vaccines, five vaccines are based on adenoviral vectors. This review is focused on understanding the safety and efficacy of the approved adenoviral vector vaccines for COVID-19, particularly highlighting the interim analysis of phase 3 clinical trials of AZD1222, Gam-Covid-Vac, Ad26.COV2.S, and AD5-nCOV vaccine. The efficacy of AZD1222, Gam-Covid-Vac, Ad26.COV2.S, and AD5-nCOV vaccine were found to be 70.4%, 95%, 66%, and 65.7%, respectively. Some serious adverse events such as deep vein thrombosis and thrombosis with thrombocytopenia syndrome were observed among AZD1222 and Ad26.COV2.S vaccinated individuals. Meanwhile, Gam-Covid-Vac and AD5- nCOV vaccines did not report any significant adverse events. In addition, we have also focused on the efficacy of these vaccines against SARS-CoV-2 variants such as B.1.1.7, B.1.351, and P.1. Although the efficacy of these approved vaccines against novel SARS-CoV-2 variants, pediatric and geriatric population and long-term efficacy remains uncertain, they are reasonably efficient in preventing mortality due to COVID-19.
Author SHANMUGAM, SINDHU
VENUGOPAL, PRIYANKA
GEORGE, MELVIN
SRIRAM, DAMAL KANDADAI
Author_xml – sequence: 1
  givenname: SINDHU
  orcidid: 0000-0001-8875-2490
  surname: SHANMUGAM
  fullname: SHANMUGAM, SINDHU
– sequence: 2
  givenname: PRIYANKA
  orcidid: 0000-0003-1830-4419
  surname: VENUGOPAL
  fullname: VENUGOPAL, PRIYANKA
– sequence: 3
  givenname: DAMAL KANDADAI
  orcidid: 0000-0003-1830-4419
  surname: SRIRAM
  fullname: SRIRAM, DAMAL KANDADAI
– sequence: 4
  givenname: MELVIN
  orcidid: 0000-0001-7101-8513
  surname: GEORGE
  fullname: GEORGE, MELVIN
BookMark eNpN0OFKwzAQAOAgE5xzz2BeoPWSps3yM3aZFkorXRfxV8nSBDZ0Gy0I_vMdfEOfxFoVPDjuOO7ux3eJJofjwSF0TSCklMTixuxPtgspUBq-knjHQ8ZoQs7QFARnAWWMTP71F2je93sYIhIxJ3yKnpSW-UbWWVngcoXlUhWlziqZY63SuqyCW7lWS6xlmmaFWuNVWeGHSmlV_J2kw_4yIAJ_vn9gOYy0qnSmHq_QuTfPvZv_1hnarFSd3gd5eZelMg8sAUoCtwDfJgIg5m7bCiG2YC1vibdDGmqAOUt4lCSxAGfAJ14I8JQlrF0YS-NohvjPX9sd-75zvjl1uxfTvTUEmhGpGZGab6RmRGpGpOgLs09Xjw
CitedBy_id crossref_primary_10_22159_ajpcr_2022_v15i12_46003
Cites_doi 10.1038/nprot.2010.134
10.4110/in.2021.21.e6
10.1136/bmj.m4750
10.1080/21645515.2020.1812313
10.1089/10430340252939023
10.1101/2020.06.12.148726
10.1056/NEJMoa2102214
10.1007/BF02789331
10.1001/jama.2021.7517
10.3390/vaccines2030624
10.1056/NEJMoa2034201
10.1111/cei.13517
10.1016/S0140-6736(21)00432-3
10.1016/j.ejphar.2020.173751
10.3390/v2081681
10.1089/hum.1998.9.17-2577
10.1038/s41591-020-1070-6
10.31219/osf.io/ypgx4
10.1016/j.tibs.2021.03.002
10.1016/S2213-2600(21)00129-6
10.1038/s41586-020-2608-y
10.21203/rs.3.rs-35891/v1
10.15585/mmwr.mm7017e4
10.1385/MB:18:1:63
10.1080/21645515.2020.1735227
10.1016/S0140-6736(20)32661-1
10.1016/S0140-6736(20)31605-6
10.1038/d41586-021-01813-2
10.1038/mtm.2016.30
10.1016/S1473-3099(20)30160-2
10.1038/s41591-021-01408-4
10.1016/j.antiviral.2020.104742
10.1016/S0140-6736(21)00234-8
10.1016/S0140-6736(21)00628-0
10.3389/fmolb.2021.635337
ContentType Journal Article
DBID AAYXX
CITATION
DOI 10.22159/ajpcr.2022.v15i7.44261
DatabaseName CrossRef
DatabaseTitle CrossRef
DatabaseTitleList CrossRef
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 0974-2441
EndPage 16
ExternalDocumentID 10_22159_ajpcr_2022_v15i7_44261
GroupedDBID ---
23N
2WC
53G
5VS
AAYXX
ADBBV
ALMA_UNASSIGNED_HOLDINGS
BAWUL
CITATION
DIK
E3Z
GX1
HH5
KQ8
M~E
OK1
RNS
TR2
ID FETCH-LOGICAL-c1021-e80fd690057ebd999b0cc7d1fcd1fa2a04ec17366590ea0f6f990f2464d8ac253
ISSN 0974-2441
IngestDate Fri Aug 23 00:35:21 EDT 2024
IsPeerReviewed false
IsScholarly true
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c1021-e80fd690057ebd999b0cc7d1fcd1fa2a04ec17366590ea0f6f990f2464d8ac253
ORCID 0000-0003-1830-4419
0000-0001-7101-8513
0000-0001-8875-2490
PageCount 11
ParticipantIDs crossref_primary_10_22159_ajpcr_2022_v15i7_44261
PublicationCentury 2000
PublicationDate 2022-07-07
PublicationDateYYYYMMDD 2022-07-07
PublicationDate_xml – month: 07
  year: 2022
  text: 2022-07-07
  day: 07
PublicationDecade 2020
PublicationTitle Asian journal of pharmaceutical and clinical research
PublicationYear 2022
References 957924
957968
957925
957969
957926
957927
957928
957929
957971
957972
957973
957930
957974
957931
957975
957932
957976
957933
957977
957934
957978
957970
957935
957979
957936
957937
957938
957939
957982
957983
957940
957984
957941
957985
957942
957986
957943
957987
957944
957988
957945
957989
957980
957981
957946
957947
957948
957949
957993
957950
957994
957951
957995
957952
957953
957954
957955
957956
957990
957991
957992
957957
957958
957959
957960
957961
957962
957963
957920
957964
957921
957965
957922
957966
957923
957967
References_xml – ident: 957978
– ident: 957926
– ident: 957951
– ident: 957940
  doi: 10.1038/nprot.2010.134
– ident: 957941
  doi: 10.4110/in.2021.21.e6
– ident: 957973
  doi: 10.1136/bmj.m4750
– ident: 957925
  doi: 10.1080/21645515.2020.1812313
– ident: 957961
– ident: 957938
  doi: 10.1089/10430340252939023
– ident: 957949
– ident: 957968
– ident: 957985
  doi: 10.1101/2020.06.12.148726
– ident: 957987
  doi: 10.1056/NEJMoa2102214
– ident: 957988
– ident: 957935
  doi: 10.1007/BF02789331
– ident: 957960
  doi: 10.1001/jama.2021.7517
– ident: 957970
– ident: 957931
  doi: 10.3390/vaccines2030624
– ident: 957974
– ident: 957993
– ident: 957955
– ident: 957957
  doi: 10.1056/NEJMoa2034201
– ident: 957959
– ident: 957954
– ident: 957929
  doi: 10.1111/cei.13517
– ident: 957950
– ident: 957923
– ident: 957946
  doi: 10.1016/S0140-6736(21)00432-3
– ident: 957928
  doi: 10.1016/j.ejphar.2020.173751
– ident: 957981
– ident: 957984
  doi: 10.1101/2020.06.12.148726
– ident: 957969
– ident: 957937
  doi: 10.3390/v2081681
– ident: 957939
  doi: 10.1089/hum.1998.9.17-2577
– ident: 957956
  doi: 10.1038/s41591-020-1070-6
– ident: 957989
– ident: 957932
  doi: 10.31219/osf.io/ypgx4
– ident: 957942
  doi: 10.1016/j.tibs.2021.03.002
– ident: 957980
  doi: 10.1016/S2213-2600(21)00129-6
– ident: 957943
  doi: 10.1038/s41586-020-2608-y
– ident: 957971
– ident: 957933
– ident: 957964
  doi: 10.21203/rs.3.rs-35891/v1
– ident: 957979
– ident: 957962
  doi: 10.15585/mmwr.mm7017e4
– ident: 957958
– ident: 957975
– ident: 957992
– ident: 957930
– ident: 957936
  doi: 10.1385/MB:18:1:63
– ident: 957947
– ident: 957924
– ident: 957963
– ident: 957982
– ident: 957966
– ident: 957920
– ident: 957972
– ident: 957995
– ident: 957921
  doi: 10.1080/21645515.2020.1735227
– ident: 957945
  doi: 10.1016/S0140-6736(20)32661-1
– ident: 957965
  doi: 10.1016/S0140-6736(20)31605-6
– ident: 957953
  doi: 10.1038/d41586-021-01813-2
– ident: 957976
– ident: 957991
– ident: 957977
– ident: 957934
  doi: 10.1038/mtm.2016.30
– ident: 957944
  doi: 10.1016/S1473-3099(20)30160-2
– ident: 957948
  doi: 10.1038/s41591-021-01408-4
– ident: 957967
– ident: 957983
– ident: 957990
– ident: 957922
  doi: 10.1016/j.antiviral.2020.104742
– ident: 957952
  doi: 10.1016/S0140-6736(21)00234-8
– ident: 957986
  doi: 10.1016/S0140-6736(21)00628-0
– ident: 957927
  doi: 10.3389/fmolb.2021.635337
– ident: 957994
SSID ssj0000395717
Score 2.2923567
Snippet The novel coronavirus and its emerging variants have continued to affect 50.4 million people worldwide, increasing the need for safe and effective vaccines....
SourceID crossref
SourceType Aggregation Database
StartPage 6
Title EVALUATION OF ADENOVIRAL VECTOR-BASED VACCINES FOR PREVENTION OF COVID-19 – AN OVERVIEW
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LjpswFLXS6aabqk_1LS-q2TCkQMAkSzcQkk4CEQkos0JgG7VdpFGbqTRd9R_6H_2ofkmvTXh0FKmdLkDI4Cvje8R9cB8IvWbMtASIVr00haHbJhgoueAETBU-JA7LjULIROFFSKaJ_W7jbHq9n52opct90WffjuaV_A9XYQz4KrNkb8DZhigMwDXwF87AYTj_E4_9lM6Tqm9ONNFgT8MoncV0rqX-eB3F-lu68j0tpeOx7K2hgcEndzz1w3rKGJ73dHOk1TEPA43CjdSPm5iJukKtSrbs1JnYvf_DGa7S4-osy0MFocbTvJrScJEEdKF8rbPQmyb1LVhMEkRLOlfqbDy7oOF5A6pVDG-jJnkgG-baOQ096tHG0Rv4URyocM6FP09nYdeFYVXhrm7XF-naOugZFcjEkbHq60o6YrrK0LwuACzQYGQB1fzjjslqr5bV_2o6H9y-LU3FVubV__mvicImQBFMI0UqU4QySShThDJF6Ba6bbkjR4aQBhuz8ekZ8qenavLcrL4KKVS03hxfVEch6mg263vo7sEkwbTC133UE9sH6HRZ8ffqDK_bFL0vZ_gUL9tq51cP0UULQhxNcAtC3AUhrkGIAYS4BaGcUoMQ__r-A1MYOsDvEUom_no81Q_9OnQmG8TrYmiUnIxkfrMoOFgehcGYy82SwZFbuWELZroDQpyRIXKjJCWoQqVlE5sPc2Y5g8foZPtpK54gbDCz4I7L3BJU5mJU5pxwMF3gg8M5Mbj7FBn1pmW7qixL9heePbv5lOfoTgvXF-hk__lSvAQddF-8Uoz_DdI7cdU
link.rule.ids 315,786,790,27955,27956
linkProvider Geneva Foundation for Medical Education and Research
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=EVALUATION+OF+ADENOVIRAL+VECTOR-BASED+VACCINES+FOR+PREVENTION+OF+COVID-19+%E2%80%93+AN+OVERVIEW&rft.jtitle=Asian+journal+of+pharmaceutical+and+clinical+research&rft.au=SHANMUGAM%2C+SINDHU&rft.au=VENUGOPAL%2C+PRIYANKA&rft.au=SRIRAM%2C+DAMAL+KANDADAI&rft.au=GEORGE%2C+MELVIN&rft.date=2022-07-07&rft.issn=0974-2441&rft.eissn=0974-2441&rft.spage=6&rft.epage=16&rft_id=info:doi/10.22159%2Fajpcr.2022.v15i7.44261&rft.externalDBID=n%2Fa&rft.externalDocID=10_22159_ajpcr_2022_v15i7_44261
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0974-2441&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0974-2441&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0974-2441&client=summon